Follistatin-344 (FS-344) and Follistatin-315 (FS-315) are alternative splice variants of the FST gene that differ in their C-terminal sequence composition. FS-344 contains an additional peptide region associated with interactions involving heparan sulfate-containing structures, influencing its localization and distribution characteristics.

FS-315 lacks this extension and displays different extracellular distribution properties. These structural differences make isoform selection an important consideration in studies investigating ligand sequestration dynamics, TGF-β superfamily signaling, extracellular protein interactions, and growth factor distribution mechanisms.

Follistatin functions as a broad-spectrum extracellular binding protein for multiple TGF-β superfamily ligands. Its highest-affinity interactions occur with activin family members, while additional binding activity has been documented for myostatin (GDF-8) and selected bone morphogenetic proteins (BMPs).

Because follistatin interacts with several ligand families rather than a single target, it is widely used in studies examining activin signaling, myostatin biology, BMP-associated pathways, receptor-ligand competition, and cross-talk within TGF-β superfamily signaling networks.

Extensive experimental research has demonstrated that follistatin modulates TGF-β superfamily signaling through direct ligand sequestration, preventing receptor engagement and downstream Smad-dependent signal transduction.

Studies utilizing recombinant protein administration, transgenic expression systems, gene-transfer approaches, and in vitro signaling models have consistently shown suppression of activin-, myostatin-, and BMP-associated signaling pathways.

These findings have established follistatin as a widely used research tool for investigating extracellular growth factor regulation, ligand-neutralization mechanisms, Smad signaling networks, and TGF-β superfamily pathway biology.